Please login to the form below

Not currently logged in
Email:
Password:

biologic

This page shows the latest biologic news and features for those working in and with pharma, biotech and healthcare.

Sanofi appoints ex-Roche Reed as new R&D head

Sanofi appoints ex-Roche Reed as new R&D head

The Paris-headquartered firm also secured two major acquisitions in January, buying US haemophilia specialist Bioverativ for $11.6 billion and Belgium’s next-generation biologics firm Ablynx for 3.9

Latest news

More from news
Approximately 17 fully matching, plus 546 partially matching documents found.

Latest Intelligence

  • Deal Watch January 2018

    Jill Ogden has over 30 years of commercial and R&D experience in the biopharmaceuticals and healthcare industries and provides our biologics, early stage deals and platform technologies expertise.

  • The good, the bad and the ugly The good, the bad and the ugly

    Humira is entrenched as a first-line biologic for the treatment of numerous conditions - and despite the EU launch of biosimilars in 2018, we anticipate that it will remain a ... Its revenues grew by a further 9% last year. “A large percentage of this

  • The tipping point The tipping point

    Biologics represent a significant proportion of these innovative medicines and a substantial portion of the global drugs budget. ... In 2016 biologics accounted for 17% of global medicines spend - that’s about 175bn.

  • Biologic or biosimilar: what are prescribers thinking? Biologic or biosimilar: what are prescribers thinking?

    Biologic or biosimilar: what are prescribers thinking? Biosimilars are raising their competitive game, but are physicians convinced? ... And how do these factors affect the ultimate choice of a biologic vs biosimilar?

  • Pushing the accelerator Pushing the accelerator

    What is the limiting factor? While software can’t speed up the research to develop the molecule or biologic, it can have a significant impact on speeding up the process.

More from intelligence
Approximately 2 fully matching, plus 62 partially matching documents found.

Latest appointments

More from appointments
Approximately 7 fully matching, plus 43 partially matching documents found.

Latest from PMHub

  • Webcast: Biosimilars: Friend or Foe to Healthcare?

    Webcast: Biosimilars: Friend or Foe to Healthcare? Understanding the opportunities for biosimilars and the threats to innovator biologics. ... Gain greater insight into what companies entering the market need to do to effectively launch their follow-on

  • Infographic: RA Perceptions

    Partnership. An infographic highlights the key findings from the study. Biologic agents with novel mechanisms of action (such as Roche’ s RoActemra) are expected to outperform the overall EU biologics market ... Biosimilars (the approved follow-on

  • Biosimilars: Getting the flock to market

    originator biologic agent, offering comparable efficacy and safety but with a lower acquisition cost. ... So biosimilars not only increase patient access to tried and trusted biologics, they may accelerate adoption of new agents.

  • Infographic: PsO market snapshot

    Infographic: PsO market snapshot. An overview of the PsO biologic and systemic patient. ... The snapshot features profile data for patients treated with biologic and systemic agents and looks at disease remission within these patient groups.

  • Infographic: RA market snapshot

    Infographic: RA market snapshot. An overview of the RA biologic patient. ... Our RA market snapshot will provide you with an introduction to the treatment pathways followed by RA patients treated with biologic agents.

More from PMHub
Approximately 7 fully matching, plus 33 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Grace Communications

Grace Communications is a creative agency specialising in healthcare communication and understanding people's personality types....

Latest intelligence

Island
Pharma’s isolated islands of innovation
With service design and technology often failing the patient, why perspective on improving outcomes need to change...
Uncertainty, austerity and Brexit
What does it mean for the life science sector?...
The Holy Grail of HCP Access
This is the data you need to gain access....

Infographics